Crinetics Pharmaceuticals, Inc. (CRNX)
NASDAQ: CRNX · Real-Time Price · USD
46.67
-0.75 (-1.58%)
At close: Dec 5, 2025, 4:00 PM EST
46.60
-0.07 (-0.15%)
After-hours: Dec 5, 2025, 5:48 PM EST
Crinetics Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 10 professional analysts, the 12-month price target for Crinetics Pharmaceuticals stock ranges from a low of $40 to a high of $108. The average analyst price target of $71 forecasts a 52.13% increase in the stock price over the next year.
Price Target: $71.00 (+52.13%)
Analyst Consensus: Buy
* Price targets were last updated on Nov 7, 2025.
Analyst Ratings
The average analyst rating for Crinetics Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 3 |
| Buy | 5 | 2 | 6 | 6 | 6 | 6 |
| Hold | 1 | 1 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 7 | 12 | 12 | 12 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citizens | Citizens | Buy Maintains $143 → $108 | Buy | Maintains | $143 → $108 | +131.41% | Nov 7, 2025 |
| Oppenheimer | Oppenheimer | Buy Maintains $73 → $87 | Buy | Maintains | $73 → $87 | +86.42% | Sep 30, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $65 → $77 | Buy | Maintains | $65 → $77 | +64.99% | Sep 29, 2025 |
| Leerink Partners | Leerink Partners | Buy Maintains $80 → $88 | Buy | Maintains | $80 → $88 | +88.56% | Sep 29, 2025 |
| Goldman Sachs | Goldman Sachs | Hold Maintains $35 → $40 | Hold | Maintains | $35 → $40 | -14.29% | Sep 26, 2025 |
Financial Forecast
Revenue This Year
5.46M
from 1.04M
Increased by 425.31%
Revenue Next Year
56.95M
from 5.46M
Increased by 943.50%
EPS This Year
-5.11
from -3.69
EPS Next Year
-5.40
from -5.11
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 10.0M | 117.7M | ||||
| Avg | 5.5M | 57.0M | ||||
| Low | 2.5M | 24.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 863.6% | 2,056.1% | ||||
| Avg | 425.3% | 943.5% | ||||
| Low | 135.8% | 350.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -5.09 | -4.14 | ||||
| Avg | -5.11 | -5.40 | ||||
| Low | -5.09 | -6.90 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.